Journal of Pharmacokinetics and Biopharmaceutics

, Volume 20, Issue 5, pp 529–556 | Cite as

Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine

  • Marie Davidian
  • A. Ronald Gallant


The seminonparametric (SNP) method, popular in the econometrics literature, is proposed for use in population pharmacokinetic analysis. For data that can be described by the nonlinear mixed effects model, the method produces smooth nonparametric estimates of the entire random effects density and simultaneous estimates of fixed effects by maximum likelihood. A graphical modelbuilding strategy based on the SNP method is described. The methods are illustrated by a population analysis of plasma levels in 136 patients undergoing oral quinidine therapy.

Key words

population pharmacokinetics nonlinear mixed effects models density estimation nonparametric estimation maximum likelihood quinidine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. L. Beal and L. B. Sheiner. Estimating population kinetics.CRC Crit. Rev. Biomed. Eng. 8:195–222 (1982).Google Scholar
  2. 2.
    J. L. Steiner, A. Mallet, J. L. Golmard, and J. F. Boisvieux. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effect model.Drug Metab. Rev. 15:265–292 (1984).CrossRefGoogle Scholar
  3. 3.
    S. L. Beal and L. B. Sheiner. Methodology of population pharmacokinetics. In E. R. Garrett and J. L. Hirtz (eds.),Drug Fate and Metabolism-Methods and Techniques, Vol. 5, Marcel Dekker, New York, 1985, pp. 135–83.Google Scholar
  4. 4.
    L. B. Sheiner and T. M. Ludden. Population pharmacokinetics/dynamics.Ann. Rev. Pharmacol. Toxicol. 32:185–209 (1992).CrossRefGoogle Scholar
  5. 5.
    S. Vozeh, R. Hillman, M. Wandell, T. M. Ludden, and L. B. Sheiner. Computer-assisted drug assay interpretation based on Bayesian estimation of individual pharmacokinetics: application to lidocaine.Ther. Drug Monit. 7:66–73 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    A. Mallet. A maximum likelihood estimation method for random coefficient regression models.Biometrika 73:645–656 (1986).CrossRefGoogle Scholar
  7. 7.
    A. Mallet, F. Mentré, J-L Steimer, and F. Lokiec. Nonparametic maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.J. Pharmacokin. Biopharm. 16:311–327 (1988).CrossRefGoogle Scholar
  8. 8.
    A. R. Gallant and D. W. Nychka. Seminonparametric maximum likelihood estimation.Econometrica 55:363–390 (1987).CrossRefGoogle Scholar
  9. 9.
    A. R. Gallant and G. E. Tauchen. Seminonparametric estimation of conditionally constrained heterogeneous processes: asset pricing applications.Econometrica 57:1091–1120 (1989).CrossRefGoogle Scholar
  10. 10.
    A. R. Gallant, P. E. Rossi, and G. E. Tauchen. Stock prices and volume.Rev. Financ. Stud. 5:199–242 (1992).CrossRefGoogle Scholar
  11. 11.
    A. D. Brunner. Conditional asymmetries in real GNP: a seminonparametric approach.J. Bus. Econ. Statist. 10:65–72 (1992).Google Scholar
  12. 12.
    M. Davidian and A. R. Gallant. The nonlinear mixed effects model with a smooth random effects density. Institute of Statistics Mimeo Series No. 2206. North Carolina State University, Raleigh, 1992.Google Scholar
  13. 13.
    I. Elbadawi, A. R. Gallant, and G. Souza. An elasticity can be estimated consistently without a priori knowledge of functional form.Econometrica 51:1731–1752 (1983).CrossRefGoogle Scholar
  14. 14.
    A. R. Gallant. Identification et convergence en regression semi-nonparamétrique.Ann. INSEE 59/60:239–267 (1985).Google Scholar
  15. 15.
    P. O. Maitre, M. Buhrer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.J. Pharmacokin. Biopharm. 19:377–384 (1991).CrossRefGoogle Scholar
  16. 16.
    J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokineticpharmacodynamic models.J. Pharmacokin. Biopharm. 20:511–529 (1992).CrossRefGoogle Scholar
  17. 17.
    S. L. Beal and L. B. Sheiner. Heteroscedastic nonlinear regression.Technometrics 30:327–338 (1988).CrossRefGoogle Scholar
  18. 18.
    C. N. Verme, T. M. Ludden, W. A. Clementi, and S. C. Harris. Pharmacokinetics of quinidine in male patients: A population analysis.Clin. Pharmacokin. 22:468–480 (1992).CrossRefGoogle Scholar
  19. 19.
    M. S. Driscoll, T. M. Ludden, D. T. Casto, and L. C. Littlefield. Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.J. Pharmacokin. Biopharm. 17:141–168 (1989).CrossRefGoogle Scholar
  20. 20.
    N. L. Johnson and S. Kotz.Continuous Univariate Distributions, Wiley, New York, 1970.Google Scholar
  21. 21.
    B. W. Silverman.Density Estimation for Statistics and Data Analysis, Chapman and Hall, London, 1986.CrossRefGoogle Scholar
  22. 22.
    B. J. Eastwood. Asymptotic normality and consistency of semi-nonparametric regression estimators using an upward F test truncation rule.J. Econometrics 48:151–182 (1991).CrossRefGoogle Scholar
  23. 23.
    B. M. Potscher. Model selection under nonstationarity: autoregressive models and stochastic linear models.Ann. Statist. 17:347–370 (1989).CrossRefGoogle Scholar
  24. 24.
    E. J. Hannan. Rational transfer function approximation.Statist. Sci. 2:1029–1054 (1987).Google Scholar
  25. 25.
    A. R. Gallant.Nonlinear Statistical Models, Wiley, New York, 1987.CrossRefGoogle Scholar
  26. 26.
    H. R. Ochs, D. J. Greenblatt, and E. Woo. Clinical pharmacokinetics of quinidine.Clin. Pharmacokin. 5:150–168 (1980).CrossRefGoogle Scholar
  27. 27.
    K. Fattinger, S. Vozeh, H. R. Ha, M. Borner, and F. Follath. Population pharmacokinetics of quinidine.Br. J. Clin. Pharmacol. 31:279–286 (1991).PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    W. A. Mahon, M. Mayerson, and T. Inaba. Disposition kinetics of two oral forms of quinidine.Clin. Pharmacol. Ther. 9:566–575 (1976).Google Scholar
  29. 29.
    American Statistical Association.Proceedings of the Biopharmaceutical Section, Annual Meetings, Boston, 1992, American Statistical Association, Alexandria, VA, 1992.Google Scholar
  30. 30.
    R. A. Becker, J. M. Chambers, and A. Wilks.The New S Language, Wadsworth and Brooks, Pacific Grove, CA, 1988.Google Scholar
  31. 31.
    S. L. Beal and L. B. Sheiner.NONMEM User's Guides. NONMEM Project Group, University of California, San Francisco, 1989.Google Scholar
  32. 32.
    S. L. Beal. Population pharmacokinetic data and parameter estimation based on their first two statistical moments.Drug Metab. Rev. 15:173–193 (1984).PubMedCrossRefGoogle Scholar
  33. 33.
    L. B. Sheiner and S. L. Beal. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexperimental model: Routine clinical pharmacokinetic data.J. Pharmacokin. Biopharm. 11:303–319 (1983).CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1992

Authors and Affiliations

  • Marie Davidian
    • 1
  • A. Ronald Gallant
    • 1
  1. 1.Department of StatisticsNorth Carolina State UniversityRaleigh

Personalised recommendations